TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment of MDS
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 19, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Therapies for myelodysplastic syndromes (MDS) are initiated in patients with a shorter predicted survival or in patients with clinically significant cytopenias. The impact of most MDS therapies on survival remains unproven.
Treatment options:
Supportive care.
Source links and citations
Disease-modifying agents.
Source links and citations
Disease-modifying agents.
Immunosuppressive therapy.
Source links and citations
Disease-modifying agents.
DNA methyltransferase inhibitors.
Source links and citations
Disease-modifying agents.
Acute myeloid leukemia (AML) induction-type chemotherapy.
Source links and citations
Allogeneic hematopoietic stem cell transplant (HSCT).
Source links and citations
Continue within this section
Preserved source evidence · Not medical advice